Propanc Biopharma, Inc.
PPCB
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.39M
Close$
Share Statistics
| Market cap | $1.39 Million |
|---|---|
| Enterprise Value | $2.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-371.25 |
| Beta | 3.33 |
| Outstanding Shares | 897,099 |
Return
| Return on Equity | -186.82% |
|---|---|
| Return on Assets | -128.10% |
| Return on Invested Capital | -163.04% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.02 |
| Price to Sales | - |
| Price to Book Ratio | 0.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.14 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Propanc Biopharma, Inc.
2 employees
CEO: James Nathanielsz Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading ...